Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer

Open access

Abstract

Gastric cancer (GC) represents a significant burden of cancer-related mortality worldwide, underscoring an urgent need for the development of early detection strategies and precise postoperative interventions. However, the identification of non-invasive biomarkers for early diagnosis and patient risk stratification remains underexplored. Here, we conduct a targeted metabolomics analysis of 702 plasma samples from multi-center participants to elucidate the GC metabolic reprogramming. Our machine learning analysis reveals a 10-metabolite GC diagnostic model, which is validated in an external test set with a sensitivity of 0.905, outperforming conventional methods leveraging cancer protein markers (sensitivity < 0.40). Additionally, our machine learning-derived prognostic model demonstrates superior performance to traditional models utilizing clinical parameters and effectively stratifies patients into different risk groups to guide precision interventions. Collectively, our findings reveal the metabolic landscape of GC and identify two distinct biomarker panels that enable early detection and prognosis prediction respectively, thus facilitating precision medicine in GC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-46043-y

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic overview of the study. Overview of the study design. The illustration was created with a full license on BioRender.com. A total of 702 individuals were included in the study, and their plasma samples underwent targeted metabolomics analysis. The metabolic profiles of gastric cancer (GC) patients and non-GC controls (NGC) in Cohort 1 (n = 426) were compared to depict the metabolic reprogramming in GC. Using the metabolomics data from Cohort 1 and machine learning techniques, a diagnostic model for GC (10-DM model) was created and validated. This model was further verified in the test set 2 (Cohort 2, n = 95). Metabolomics data from Cohort 3 (n = 181) patients and their clinical features were analyzed using a machine learning algorithm to develop a prognostic model (28-PM model). The performance of these two models was benchmarked against clinically used biomarkers/clinical features. Different colored triangles in the figure represent various participant groups used for model construction, validation, and comparison processes. Source data are provided as a Source Data file.
Fig. 1 Schematic overview of the study. Overview of the study design. The illustration was created with a full license on BioRender.com. A total of 702 individuals were included in the study, and their plasma samples underwent targeted metabolomics analysis. The metabolic profiles of gastric cancer (GC) patients and non-GC controls (NGC) in Cohort 1 (n = 426) were compared to depict the metabolic reprogramming in GC. Using the metabolomics data from Cohort 1 and machine learning techniques, a diagnostic model for GC (10-DM model) was created and validated. This model was further verified in the test set 2 (Cohort 2, n = 95). Metabolomics data from Cohort 3 (n = 181) patients and their clinical features were analyzed using a machine learning algorithm to develop a prognostic model (28-PM model). The performance of these two models was benchmarked against clinically used biomarkers/clinical features. Different colored triangles in the figure represent various participant groups used for model construction, validation, and comparison processes. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Reprogrammed plasma metabolic landscape of GC patients compared with non-GC controls. a Principal Component Analysis (PCA) of the Cohort 1 (n = 426) plasma-targeted metabolomics data comparing GC patients (colored in purple) and NGC controls (colored in green). b Volcano plot of the detected metabolites in Cohort 1 plasma metabolomics (GC patients versus NGC controls). Significantly differential metabolites are colored in purple (upregulated) and green (downregulated); the others are colored in gray. Two-sided Wilcoxon rank-sum test followed by Benjamini–Hochberg (BH) multiple comparison test with false discovery rate (FDR) < 0.05 and fold change (FC) > 1.25 or < 0.8. c Mfuzz clustering of metabolic trajectories during GC progression using the differential metabolites according to the metabolic changes’ similarity. Representative metabolites of each cluster are presented on the side. d Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways enriched by significantly differential metabolites between GC patients and NGC controls. One-sided Fisher’s exact test followed by BH multiple comparison tests was used and only pathways with FDR < 0.05 were presented. Source data are provided as a Source Data file.
Fig. 2 Reprogrammed plasma metabolic landscape of GC patients compared with non-GC controls. a Principal Component Analysis (PCA) of the Cohort 1 (n = 426) plasma-targeted metabolomics data comparing GC patients (colored in purple) and NGC controls (colored in green). b Volcano plot of the detected metabolites in Cohort 1 plasma metabolomics (GC patients versus NGC controls). Significantly differential metabolites are colored in purple (upregulated) and green (downregulated); the others are colored in gray. Two-sided Wilcoxon rank-sum test followed by Benjamini–Hochberg (BH) multiple comparison test with false discovery rate (FDR) < 0.05 and fold change (FC) > 1.25 or < 0.8. c Mfuzz clustering of metabolic trajectories during GC progression using the differential metabolites according to the metabolic changes’ similarity. Representative metabolites of each cluster are presented on the side. d Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways enriched by significantly differential metabolites between GC patients and NGC controls. One-sided Fisher’s exact test followed by BH multiple comparison tests was used and only pathways with FDR < 0.05 were presented. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Machine learning-derived prediction model based on plasma metabolome for GC diagnosis. a Design of the modeling workflow. LASSO regression and random forest algorithm were adopted for feature selection and model training. The 10-DM model was validated in a test set and an external test set. The illustration was created with a full license on BioRender.com. b The Receiver operating characteristic (ROC) curve for the diagnosis of GC patients in the test set 1. A 95% confidence interval was calculated based on the mean and covariance of one thousand random sampling tests. c Contribution of the ten metabolites to the 10-DM model. d–g, The prediction performance of the 10-DM model for distinguishing GC (colored in purple) from NGC (colored in green) in the test set 1 (d) and the test set 2 (e) and for distinguishing stage I GC patients (stage IA colored in yellow and stage IB colored in brown) from NGC in the test set 1 (f) and the test set 2 (g). The dotted line represented the cutoff value of 0.50 used to separate the predicted NGC (on the left side) from GC (on the right side). Source data are provided as a Source Data file.
Fig. 3 Machine learning-derived prediction model based on plasma metabolome for GC diagnosis. a Design of the modeling workflow. LASSO regression and random forest algorithm were adopted for feature selection and model training. The 10-DM model was validated in a test set and an external test set. The illustration was created with a full license on BioRender.com. b The Receiver operating characteristic (ROC) curve for the diagnosis of GC patients in the test set 1. A 95% confidence interval was calculated based on the mean and covariance of one thousand random sampling tests. c Contribution of the ten metabolites to the 10-DM model. d–g, The prediction performance of the 10-DM model for distinguishing GC (colored in purple) from NGC (colored in green) in the test set 1 (d) and the test set 2 (e) and for distinguishing stage I GC patients (stage IA colored in yellow and stage IB colored in brown) from NGC in the test set 1 (f) and the test set 2 (g). The dotted line represented the cutoff value of 0.50 used to separate the predicted NGC (on the left side) from GC (on the right side). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 The prognostic model outperformed clinical parameters in predicting outcomes of GC patients. a Schematic outline of the prognostic model design. S survived, D deceased. b ROC curve analysis of the test set. 95% CI was calculated based on the mean and covariance of one thousand random sampling tests. c Forest plot of clinical parameters with significant prognostic relevance identified by univariate Cox regression analysis. Parameters with a P < 0.05 were considered statistically significant and represented by green lines. The center dots and lines represent HR and 95% Cl scaled by log 10. EGC, early gastric cancer. P-values of TNM staging, macroscopic appearance, and vascular tumor embolus were calculated based on data from n = 181, 180, and 180 independent samples respectively. d C-index values comparison of the macroscopic appearance, TNM staging, vascular tumor embolus, and the 28-PM model in the test set (n = 60). C-index and the 95% Cl were presented under the relative colored bars. e Prognostic prediction of the test set patients (n = 60) using the 28-PM model. The dotted line drawn at the cutoff value of 2.1 divided the patients into high- and low-risk groups. Green circles and gray circles represent survived and deceased in the test set. The arrow pointed out the deceased patient dying of a heart attack. f Kaplan–Meier curves showing the overall survival (OS) and disease-free survival (DFS) of test set GC patients (n = 60) stratified by prognostic risk scores (cutoff = 2.1). P-values were calculated with a two-sided log-rank test. g The high-risk group presented a higher proportion of deceased and relapse/metastasis. A two-sided Fisher’s exact test was used to calculate the P-value. Source data are provided as a Source Data file.
Fig. 4 The prognostic model outperformed clinical parameters in predicting outcomes of GC patients. a Schematic outline of the prognostic model design. S survived, D deceased. b ROC curve analysis of the test set. 95% CI was calculated based on the mean and covariance of one thousand random sampling tests. c Forest plot of clinical parameters with significant prognostic relevance identified by univariate Cox regression analysis. Parameters with a P < 0.05 were considered statistically significant and represented by green lines. The center dots and lines represent HR and 95% Cl scaled by log 10. EGC, early gastric cancer. P-values of TNM staging, macroscopic appearance, and vascular tumor embolus were calculated based on data from n = 181, 180, and 180 independent samples respectively. d C-index values comparison of the macroscopic appearance, TNM staging, vascular tumor embolus, and the 28-PM model in the test set (n = 60). C-index and the 95% Cl were presented under the relative colored bars. e Prognostic prediction of the test set patients (n = 60) using the 28-PM model. The dotted line drawn at the cutoff value of 2.1 divided the patients into high- and low-risk groups. Green circles and gray circles represent survived and deceased in the test set. The arrow pointed out the deceased patient dying of a heart attack. f Kaplan–Meier curves showing the overall survival (OS) and disease-free survival (DFS) of test set GC patients (n = 60) stratified by prognostic risk scores (cutoff = 2.1). P-values were calculated with a two-sided log-rank test. g The high-risk group presented a higher proportion of deceased and relapse/metastasis. A two-sided Fisher’s exact test was used to calculate the P-value. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 244

Metadata

Authors
Chen, Y., Wang, B., Zhao, Y., Shao, X., Wang, M., Ma, F., Yang, L., Nie, M., Jin, P., Yao, K., Song, H., Lou, S., Wang, H., Yang, T., Tian, Y., Han, P., & Hu, Z.
Affiliations
  • Tsinghua University (CN)
  • Center for Life Sciences (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Harbin Medical University (CN)
  • Fudan University (CN)
Corresponding author
  • Tian, Yantao
  • Han, Peng
  • Hu, Zeping
Venue
Nature Communications
Published
2024-02-23
Volume
15
Issue
1
Pages
1657-1657
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4392125974
Cited by
244
References
80
Citations by year
2026: 102 · 2025: 108 · 2024: 34
FWCI
32.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Harbin Medical University
  • National Natural Science Foundation of China (92057209, 82072640, 81973355)
  • Chinese Academy of Medical Sciences
  • Peking Union Medical College
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Physical Sciences › Engineering › Biomedical Engineering › Advanced Chemical Sensor Technologies
Keywords
gastric cancer, plasma metabolomics, targeted metabolomics, non-invasive biomarkers, early diagnosis, prognostic model, risk stratification, metabolic reprogramming, machine learning prediction models, precision medicine
MeSH terms
Machine Learning, Metabolic Reprogramming, Humans, Stomach Neoplasms, Metabolomics, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer. https://app.cochat.ai/papers/10.1038/s41467-024-46043-y
The paper
Chen, Y., Wang, B., Zhao, Y., Shao, X., Wang, M., Ma, F., Yang, L., Nie, M., Jin, P., Yao, K., Song, H., Lou, S., Wang, H., Yang, T., Tian, Y., Han, P., & Hu, Z. (2024). Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer. Nature Communications. https://doi.org/10.1038/s41467-024-46043-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.